Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

Oncologist

Volumn 12, Issue 2, 2007, Pages 191-200

  Gridelli, Cesare ^a   Maione, Paolo ^a   Del Gaizo, Filomena ^a   Colantuoni, Giuseppe ^a   Guerriero, Ciro ^a   Ferrara, Carmine ^a   Nicolella, Dario ^a   Comunale, Daniela ^a   De Vita, Alba ^a   Rossi, Antonio ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Multikinase inhibitors; NSCLC; Sorafenib; Sunitinib; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CD135 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; NAVELBINE; PACLITAXEL; PHOSPHOTRANSFERASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; HYPONATREMIA; KERATOACANTHOMA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SKIN TOXICITY; SOLID TUMOR; UNITED STATES; UNSPECIFIED SIDE EFFECT; VASCULITIS; VOMITING;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; INDOLES; LUNG NEOPLASMS; PYRIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847022313     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-2-191     Document Type: Review

References (62)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
3. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
4. Hotta K, Matsuo K, Ueoka H et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860-3867.
5. Curran WJ Jr, Scott CB, Langer CJ et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621a.
6. Hotta K, Matsuo K, Ueoka H et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: A literature based meta-analysis of randomised trials. Ann Oncol 2004;15:1782-1789.
7. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005;353:123-132.
8. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer: An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 2005;23/16S:1090s.
9. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-2555.
10. Tortora G, Caputo R, Damiano V et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003;9:866-871.
11. Ciardiello F, Troiani T, Bianco R et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for multi-target anticancer therapy. Ann Oncol 2006;17:109-114.
12. Maione P, Gridelli C, Troiani T et al. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. The Oncologist 2006;11:274-284.
13. Morabito A, De Maio E, Di Maio M et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. The Oncologist 2006;11:753-764.
14. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002;8:17-23.
15. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-420.
16. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002;8:S27-S31.
17. Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994;4:82-89.
18. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
19. Doanes AM, Hegland DD, Sethi R et al. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 1999;255:545-548.
20. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001;276:49289-49298.
21. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
22. Kimura ET, Nikiforova MN, Zhu Z et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
23. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
24. Alavi A, Hood JD, Frausto R et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003;301:94-96.
25. Hood JD, Bednarski M, Frausto R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-2407.
26. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027.
27. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295.
28. Adams J, Huang P, Patrick D. A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin Chem Biol 2002;6:486-492.
29. Wilhelm SM, Carter C, Tang LY et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2005;64:7099-7109.
30. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-3605.
31. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
32. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
33. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-1694.
34. Ratain MJ, Eisen T, Stadler WM. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
35. Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005;23/16S:4510.
36. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. J Clin Oncol 2006;24/18S:4524.
37. European Commission - Enterprise and Industry. The community Register of designated orphan medicinal products for human use. Available at: http://europa.eu.int/comm/enterprise/pharmaceuticals/register. Accessed February 5, 2006.
38. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-4300.
39. Lorigan P, Corrie P, Chao D et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J Clin Oncol 2006;24/18S:8012.
40. Amaravadi RK, Schuchter LM, Kramer A et al. Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 2006;24/18S:8009.
41. Rosen L, Mulay M, Long J et al. Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:765a.
42. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
43. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
44. Motzer RJ, Hutson TE, Tomczak P. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24/18S:LBA3.
45. Maki RG, Fletcher A, Heinrich MC et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2005;23:9011a.
46. Demetri GD, van Oosterom AT, Blackstein M et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 2005;23:4000a.
47. Casali PG, Garrett CR, Blackstein ME. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 2006;24/18S:9513.
48. Gollob JA, Wilhelm S, Carter C et al. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406.
49. Carter CA, Chen C, Brink C et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2006 May 25 [Epub ahead of print].
50. Liu B, Barrett T, Choyke P et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24/18S:17119.
51. Gatzemeier U, Blumenschein G, Fosella F. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006;24/18S:7002.
52. Gondek K, Dhanda R, Simantov R. Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib. J Clin Oncol 2006;24/18S:17085.
53. Socinski MA, Novello S, Sanchez JM. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol 2006;24/18S:7001.
54. Steinbild S, Baas F, Gmehling D et al. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. Proc Am Soc Clin Oncol 2005;23:3115a.
55. Eisen T, Ahmad T, Gore ME et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. Proc Am Soc Clin Oncol 2005;23:7508a.
56. Adjei AA, Mandrekar S, Marks RS et al. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005;23:3067a.
57. Richly H, Henning BF, Kupsch P et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-873.
58. Siu LL, Awada A, Takimoto CH et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-151.
59. Duran I, Hotte S, Hirte H et al. Dual inhibition of the MAPK pathway by combination targeted therapy: A phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors. Eur J Cancer 2006;4:167.
60. Azad NS, Posadas EM, Kwitkowski VE. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol 2006;24/18S:3004.
61. Rini BI, George DJ, Michaelson MD et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24/18S:4522.
62. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-952.